Study Shows Novel Flavoprotein Fluorescence Measure is Correlated with...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: April 25, 2024

Voices for Humanity Bears Witness to Panama's Moral Resurgence With Giselle Lima • Ouro Teams Up with Texas One Fund with Multi-Year NIL X World Wallet Financial Empowerment Program for University of Texas Stude • Leading Industry Publication: Black & Veatch Remains Among Global Critical Infrastructure Leaders as Sustainability, Decarbo • NICOLE ARI PARKER IS THE FACE OF KAREN MILLEN'S ICONS SERIES VOL. 6 • God's Mighty Hand Can Uphold His Children Even Through The Hardest Times • White House Correspondents’ Association Dinner to Welcome Hooman Shahidi, Co-founder and CEO of EVPassport, the Rapidly Gr • The Birches at Concord Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai • Orion S.A. Earns Platinum Sustainability Rating by EcoVadis • ERVIN COHEN & JESSUP PARTNER RECOGNIZED AS TOP LAWYER IN LOS ANGELES • Arcosa Publishes 2023 Sustainability Report • QuantumScape Reports First Quarter 2024 Business and Financial Results • Benchmark Senior Living at Hamden Assisted Living Community Named One of the Country's Best by U.S. News & World Report • Asahi Kasei to Construct a Lithium-ion Battery Separator Plant in Canada • Wounded Warrior Project, White House Celebrate and Honor Warriors at Annual Soldier Ride • Motlow State Community College Expands Accessibility With the Addition of YuJa Panorama Digital Accessibility Platform to Its Ed • WM Announces First Quarter 2024 Earnings • Walgreens Launches Gene and Cell Services as Part of Newly Integrated Walgreens Specialty Pharmacy Business • PONIX AWARDED $5 MILLION USDA GRANT TO BREAK "GROUND" ON CLIMATE-SMART AGRICULTURE IN GEORGIA • Bay Square at Yarmouth Assisted Living Community Named One of the Country's Best by U.S. News & World Report for Third Strai • ACTS LAW Addresses Federal Correctional Institution in Dublin Controversy

Study Shows Novel Flavoprotein Fluorescence Measure is Correlated with Age-Related Macular Degeneration (AMD) Stage

ANN ARBOR, Mich. , February 08 /Businesswire/ - OcuSciences, a medical device company developing ocular imagers to detect early disease by assessing retinal metabolic activity, today announced the publication of an Age-related Macular Degeneration (AMD) study in the Ophthalmic Surgery, Lasers and Imaging Retina journal. By quantifying the degree of retinal oxidative stress and mitochondrial dysfunction, these findings suggest that the novel FPF measure can categorize AMD patients by stage, which may better elucidate the underlying pathophysiology of AMD.

This prospective observational study, led by Rishi Singh, M.D., staff ophthalmologist at Cleveland Clinic Cole Eye Institute and president of Cleveland Clinic Martin Health, included 456 eyes (228 AMD eyes, 228 age-matched control eyes), with cohorts of early AMD, intermediate AMD, geographic atrophy (GA), and neovascular AMD. Patients were imaged with the OcuMet Beacon, OcuSciences’ flagship functional retinal imager, between August 2018 and December 2021 to capture and quantify their overall FPF intensity and FPF heterogeneity. Intermediate, geographic atrophy, and neovascular AMD correlated with significantly increased FPF intensity, while all AMD stages correlated with increased FPF heterogeneity.

“These findings suggest that mitochondrial function plays an important role in the progression of AMD,” said Dr. Singh. “The ability to quantitatively measure mitochondrial dysfunction may give us better insights into how and when to treat AMD patients.”

The OcuMet Beacon is an automated, rapid retinal imager that assesses mitochondrial function by interrogating flavoproteins. The device emits a very specific wavelength of light that excites flavoproteins in retinal mitochondria only when those mitochondria cannot efficiently produce ATP. The dysfunctional flavoproteins emit a specific wavelength that the device then captures and quantifies. Mitochondrial dysfunction has been documented as a precursor to apoptosis, or cell death.

The OcuMet Beacon is currently being used at Cole Eye Institute under Institutional Review Board.

About OcuSciences, Inc.

OcuSciences, Inc., is a commercial-stage biotechnology company developing retinal imagers to identify metabolic dysfunction occurring in the retina for the early detection of disease. Its flagship device, the OcuMet Beacon, has been developed to automatically and non-invasively assess retinal metabolic function by detecting the degree of flavoprotein fluorescence (FPF), a well-studied precursor to retinal cell death, in a patient’s eye. OcuSciences has shown preliminary clinical utility in a number of different disease states, including diabetic retinopathy, glaucoma, and age-related macular degeneration. Learn more at www.ocusciences.com.